[1]徐 杰.美沙拉嗪與柳氮磺吡啶治療潰瘍性結腸炎的效果比較[J].醫學信息,2020,(04):151-152,157.[doi:10.3969/j.issn.1006-1959.2020.04.049]
 XU Jie.Comparison of Mesalazine and Sulfasalazine in Treating Ulcerative Colitis[J].Medical Information,2020,(04):151-152,157.[doi:10.3969/j.issn.1006-1959.2020.04.049]
點擊復制

美沙拉嗪與柳氮磺吡啶治療潰瘍性結腸炎的效果比較()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
151-152,157
欄目:
藥物與臨床
出版日期:
2020-02-15

文章信息/Info

Title:
Comparison of Mesalazine and Sulfasalazine in Treating Ulcerative Colitis
文章編號:
1006-1959(2020)04-0151-03
作者:
徐 杰
(沈陽市渾南區中心醫院消化內科,遼寧 沈陽 110015)
Author(s):
XU Jie
(Department of Gastroenterology,Central Hospital of Hunnan District,Shenyang 110015,Liaoning,China)
關鍵詞:
美沙拉嗪柳氮磺吡啶潰瘍性結腸炎
Keywords:
MesalazineSulfasalazineUlcerative colitis
分類號:
R547.62
DOI:
10.3969/j.issn.1006-1959.2020.04.049
文獻標志碼:
A
摘要:
目的 比較美沙拉嗪與柳氮磺吡啶治療潰瘍性結腸炎的臨床效果。方法 選取2018年2月~2019年2月在我院診治的70例潰瘍性結腸炎患者為研究對象,采用隨機數字表法分為對照組和觀察組,各35例。對照組采用柳氮磺吡啶治療,觀察組采用美沙拉嗪治療,比較兩組臨床治療總有效率、臨床癥狀(腹瀉、腹痛、黏液便血)積分、結腸鏡檢評分、C反應蛋白水平及不良反應(惡心嘔吐、粒細胞減少、頭痛、外周血白細胞下降)發生情況。結果 觀察組臨床治療總有效率為94.28%,高于對照組的82.85%,差異有統計學意義(P<0.05);治療后兩組腹瀉、腹痛、黏液便血積分均低于治療前,且觀察組低于對照組,差異有統計學意義(P<0.05);治療后兩組結腸鏡檢評分均低于治療前,且觀察組低于對照組,差異有統計學意義(P<0.05);治療后兩組C反應蛋白水平均低是否于治療前,且觀察組低于對照組,差異有統計學意義(P<0.05);觀察組不良反應發生率為8.57%,低于對照組的22.85%,差異有統計學意義(P<0.05)。結論 美沙拉嗪治療潰瘍性結腸炎的臨床效果優于柳氮磺吡啶,有助于炎癥吸收,改善臨床癥狀,且不良反應少,值得臨床應用。
Abstract:
Objective To compare the clinical effects of mesalazine and sulfasalazine in the treatment of ulcerative colitis.Methods A total of 70 patients with ulcerative colitis diagnosed and treated in our hospital from February 2018 to February 2019 were selected as the research subjects. They were divided into the control group and the observation group by random number table method, 35 cases in each group. The control group was treated with sulfasalazine and the observation group was treated with mesalazine. The total effective rate, clinical symptoms (diarrhea, abdominal pain, mucus and blood in the stool) score, colonoscopy score, C-reactive protein level, and adverse reactions were compared between the two groups (Nausea and vomiting, granulocytopenia, headache, peripheral white blood cell decline).Results The total effective rate of clinical treatment in the observation group was 94.28%, which was higher than 82.85% in the control group,the difference was statistically significant (P<0.05).After treatment, the scores of diarrhea, abdominal pain, and mucus in the two groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). The colonoscopy scores of the two groups were lower than before treatment and the observation group was lower than the control group, the difference was statistically significant (P<0.05);The C-reactive protein level in the two groups after treatment was lower than before the treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05); the incidence of adverse reactions in the observation group was 8.57%, lower than 22.85% in the control group,the difference was statistically significant(P<0.05).Conclusion Mesalazine is superior to sulfasalazine in the treatment of ulcerative colitis, which is helpful for inflammation absorption, improves clinical symptoms, and has fewer adverse reactions, which is worthy of clinical application.

參考文獻/References:

[1]黃志養,金捷,朱麗明,等.美沙拉嗪口服聯合甲硝唑保留灌腸對潰瘍性結腸炎患者的臨床療效[J].中國基層醫藥,2017,24(8):1178-1181. [2]中華醫學會消化病學分會炎癥性腸病學組.建立我國炎癥性腸病診治中心質量控制指標的共識[J].中華內科雜志,2016, 55(7):568-571. [3]張小河.美沙拉嗪聯合益生菌與柳氮磺吡啶治療潰瘍性結腸炎的臨床療效比較[J].現代診斷與治療,2014,25(6):1279-1280. [4]夏代菊.美沙拉嗪對潰瘍性結腸炎患者臨床癥狀和結腸鏡下評分改善觀察[J].浙江臨床醫學,2014,14(9):1088-1089. [5]李楊麟,喻曉東,蘇林,等.美常安聯合柳氮磺吡啶治療潰瘍性結腸炎的療效及對血清TNF-α、IL-6、IL-8水平的影響[J].現代生物醫學進展,2016,16(10):1926-1929. [6]張樹惠.美沙拉嗪和柳氮磺吡啶對潰瘍性結腸炎患者血清炎性因子表達的影響[J].國際醫藥衛生導報,2016,22(3):375-378. [7]王爽,鄭秀艷,孫文華,等.美沙拉嗪對潰瘍性結腸炎患者血清CRP,IL-10及TNF-α水平的影響[J].現代生物醫學進展,2017,17(14):2693-2696. [8]丁海榮,王丙信,任清華,等.復方甘草酸苷聯合柳氮磺吡啶治療潰瘍性結腸炎的臨床研究[J].現代藥物與臨床,2016,31(3):367-370. [9]李楊麟,喻曉東,蘇林,等.美常安聯合柳氮磺吡啶治療潰瘍性結腸炎的療效及對血清TNF-α、IL-6、IL-8水平的影響[J].現代生物醫學進展,2016,16(10):1926-1929.

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 福建快三形态开奖结果一定牛 陕西11选五前三组遗漏 贵州十一选五软件 彩票网站平台 福彩快乐十分推算技巧 云南11选五5前三组走势图 山东福利彩票app 山东11选5 五连号遗漏 湖北快三怎么买中红号 快3单双公式技巧规律